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Introduction
Acute kidney injury (AKI) is a disorder that often compli-
cates the hospital course of patients and is associated 
with a significant mortality risk. ose patients with the 
most severe forms of AKI, who develop such significant 
solute or fluid imbalance that they are usually treated 
with renal replacement therapy (RRT), experience a 
hospital mortality of approximately 60% [1]. In spite of 
improvements in care, the mortality of AKI remains 
unacceptably high [2].
AKI is a clinical syndrome that is associated with the 
acute loss of kidney function, as evidenced by a drop in 
the glomerular filtration rate (GFR). e most common 
causes of AKI in developed countries are sepsis, circu-
latory shock, major cardiovascular surgery, and heart and 
liver failure [1]. Because decreased renal blood flow 
(RBF) is usually assumed to play a role in each of these 
conditions, the traditional teaching approach for AKI is 
that restoration of RBF is critical. e focus of therapeutic 
intervention in AKI for the past 40 years has thus been to 
restore RBF and to minimize nephrotoxic exposure. 
erapeutic clinical trials of AKI have focused on 
increasing the RBF and GFR by utilizing a variety of 
drugs (for example, dopamine, anaritide, fenoldopam) 
[3]. Unfortunately, this approach has yielded no success-
ful therapy for the treatment of AKI.
Our understanding of the pathophysiology of AKI 
is insucient
AKI is a clinical syndrome with a multitude of causes. 
Like any syndrome, AKI can be separated into suscep-
tibility and exposure. e most common susceptibilities 
for AKI are advanced age and chronic kidney disease 
(CKD). e most common exposure related to AKI is 
sepsis, which is associated with 45 to 50% of all cases of 
AKI [4]. Of note, available preclinical and human data 
suggest that septic-associated AKI is not associated with 
tubular necrosis [5,6]. ese same studies demonstrate 
that RBF in sepsis is typically increased, and that, despite 
this augmented RBF, septic patients still experience a 
drop in GFR and develop AKI (reviewed in [6]). In 
addition, the few studies that have assessed histo-
pathology in septic patients do not show evidence of 
tubular necrosis [7]. e failure to develop appropriate 
therapeutic agents for AKI may thus be due to the fact 
that the therapeutic agents being considered work via 
increasing the GFR by increasing RBF (for example, 
anaritide) – which is unlikely to benefit those patients 
with sepsis, the most common exposure associated with 
AKI.
It is logical to try and assist a failing organ by treating 
the underlying cause. Once an organ is injured, however, 
trying to force that organ to work harder may not be the 
best approach. In fact, this approach has been shown to 
be counter-pro ductive in other areas of critical care. For 
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example, the focus of therapy during myocardial infarc­
tion is twofold: treat the underlying cause and rest the 
injured organ. For example, when patients sustain a 
significant myocardial infarction, if ventricular function 
is inadequate after treatment (for example, angioplasty) 
then it is common to place an intra­aortic balloon pump 
(or in extreme cases a ventricular assist device) to 
decrease the workload on the heart [8]. Similarly, the 
thera peutic intervention in adult respira tory distress 
syndrome (ARDS) is to decrease the tidal volume, some­
times even to the point of allowing respiratory acidosis 
(permissive hypercapnia), in order to avoid exacerbating 
lung injury and thereby to improve outcomes [9].
Lessons from ARDS and potential for harm
AKI and ARDS are syndromes that have much in common. 
Both have multiple etiologies; and the most common 
cause for both ARDS and AKI is sepsis. Both syndromes 
are associated with increased mortality; and both affect 
critically ill patients, contributing to an increased risk of 
death. In addition, both syndromes typically involve a 
mechanical intervention for organ support, RRT and 
mechanical ventilation, respectively. However, the 
clinical trial endpoints of focus are quite different for AKI 
and ARDS. In ARDS, the endpoints utilized in clinical 
trials are most often both short­term disability (30­day 
mortality, ventilator­free days) and long­term disability. 
For AKI, however, the endpoints are typically only short 
term: 30­day mortality and need for RRT. The need for 
RRT is akin to the need for intubation and mechanical 
ventila tion in ARDS and yet the two endpoints are 
treated very differently. This difference is critical. The 
notion that a drug or intervention can prevent the need 
for mechanical ventilation in a patient with severe ARDS 
is not realistic. ARDS causes rapid deterioration in 
pulmonary function and organ support (for example, 
mechanical ven tila tion) is insti tuted early. Because the 
endpoint in AKI is need for RRT, there is an implicit 
expectation that a drug or inter vention can alter the 
clinical trajectory of severe AKI within a few days and 
furthermore that RRT can be safely delayed awaiting 
renal recovery. With the advent of more biologically 
compatible membranes and physiologic RRT fluids, there 
has been a secular trend of initiating RRT sooner. There­
fore, even if diagnostic techniques improve our time to 
diagnosis of AKI, do we expect a therapeutic drug or 
intervention to forestall the need for organ support within 
a short time frame (that is, 2 to 3 days)? Unlike opening an 
artery for the treatment of myocardial infarc tion, the 
kidney’s response to injury is more com plex; the renal 
vasculature, glomeruli, renal tubules, and inter stitium do 
not respond monolithically. To expect an inter ven tion or 
drug to heal the kidney and all its complex components in 
a few days is not biologically plausible.
One of the lessons of ARDS is thus to focus on realistic 
endpoints. Instead of short­term mortality and need for 
RRT, we propose that the more appropriate short­term 
endpoints in studying AKI should be short­term mortality 
and RRT­free days, or even AKI­free days (similar to the 
endpoints in ARDS).
Another critical lesson from ARDS is the potential to 
do harm. The mainstay of treatment for ARDS is to avoid 
ventilator­induced lung injury [9]. A key advance in the 
treatment of ARDS was the recognition that mechanical 
ventilation performed incorrectly can be injurious [9]. 
Similarly, the way that patients with AKI are treated can 
also be injurious. RRT must be prescribed in a thoughtful 
fashion to avoid significant adverse events. For instance, 
the use of intermittent hemodialysis in critically ill 
patients can result in significant hypotension and persis­
tent intestinal ischemia [10,11].
Fluid overload in acute kidney injury
Because classic teaching states that hypovolemia is the 
most common reversible cause of AKI, the standard 
treatment for AKI is a trial of volume (for example, 
crystalloid infusion). For the vast majority of clinicians, the 
standard approach to AKI once it is recognized is as 
follows: rule out reversible causes of AKI, discontinue 
diuretics, administer a trial of volume, stop any nephro­
toxic drugs, and rule out obstructive nephropathy. Once 
the patient is deemed optimally resuscitated, a trial of loop 
diuretics is usually conducted. This approach is reasonable 
and represents the recommended approach [12]. However, 
this approach also offers the opportunity to do harm.
A trial of volume administration is a core feature of 
most empiric AKI treatment. Not surprisingly, fluid 
overload is common in patients with AKI [13]. Fluid 
overload has been shown to be associated with increased 
mortality and increased length of stay in multiple studies, 
and has an independent effect on mortality even after the 
severity of illness and the degree of AKI are taken into 
account [13­15]. This association has been shown in 
adults and children, and prospective trials have shown 
that interventions which reduce fluid overload lead to 
more rapid liberation from mechanical ventilation and 
less renal failure [16,17].
Renal replacement therapy in acute kidney injury
For those patients with AKI who require RRT, the tech­
nical aspects of RRT have become increasingly impor tant. 
Contemporary RRT is associated with higher dosing of 
RRT as compared with historical controls. When patients 
are subjected to higher doses of RRT, they experience 
improved solute clearance and faster resolu tion of 
electrolyte and acid–base imbalances. However, these 
patients may have a higher incidence of inadequate plasma 
antibiotic levels, hypophosphatemia and hypothermia.
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Pharmacology studies assessing antibiotic levels in 
patients undergoing continuous renal replacement 
therapy (CRRT) with contemporary dosing found that 
antibiotic levels were inadequate for up to 75% of the 
antibiotics tested [18]. Appropriate and adequate 
antibiotics has been a corner stone of sepsis therapy 
[19,20], and studies such as these endorse the notion that 
antibiotics can be rendered less useful if the CRRT and 
the drug dosing are not harmonized. Similarly, patients 
undergoing CRRT are susceptible to hypophosphatemia 
[21]. Hypophospha te mia can have multiple negative 
consequences including, but not limited to, hemolysis, 
respiratory failure, rhab domyolysis, delirium and 
neutrophil dysfunction [22,23]. Another potential 
complication of RRT is hypothermia. Because of the 
extracorporeal circuit, inadequate warm ing of 
replacement fluid/dialysate can lead to hypo thermia [24]. 
In a large multicenter study of more than 10,000 patients, 
hypothermia has been shown to be a major risk factor 
associated with increased risk of mortality in critically ill 
patients [25]. Large well­powered clinical trials of 
increased doses of RRT did not proto colize these aspects 
of RRT [21,26], and some investi gators have suggested 
that inadequate control of these parameters may have 
had a significant negative impact.
Early institution of RRT is likely to have multiple 
positive effects in AKI, including improved fluid balance 
and the capacity to rest the injured kidney. However, the 
manner in which RRT is conducted in the ICU appears to 
be important. RRT must be conducted with the 
appropriate management of drug dosing, thermal 
control, volume and electrolyte balance.
Interplay of acute kidney injury and chronic kidney 
disease
Classic teaching regarding patients who survive an 
episode of AKI – in particular, acute tubular necrosis – 
states that these patients achieve full or nearly full 
recovery. This notion was based on multiple studies that 
followed survivors of AKI after hospital discharge [27]. 
More recently, from 2008 through 2012, multiple studies 
assessing unique cohorts of patients demonstrated that 
patients who survive an episode of AKI have a significant 
risk for progression to advanced CKD (stage 4/5) [28­33]. 
Moreover, there are multiple studies that have linked 
severity of AKI with increased risk of CKD progression 
[29,30,34]. In short, patients who experience a severe 
episode of AKI are at risk for incident CKD, and those 
patients with pre­existing CKD are at risk for accelerated 
progression of CKD.
Choice of endpoints for clinical trials in AKI
As discussed earlier, the short­term composite endpoint 
of death/RRT may not be appropriate. Because subsets of 
AKI patients tend to progress to CKD, medium­term 
outcomes in AKI should also be assessed. Similar to the 
pathophysiology of ARDS, wherein a fibroproliferative 
phase follows the initial exudative phase, subsets of 
patients with AKI experience ongoing fibrosis that tends 
to persist after injury. Clinical epidemiologic studies 
confirm that about 15 to 20% of patients who experience 
AKI rapidly progress to advanced­stage CKD within 20 
to 24  months [28]. Given that CKD is a significant risk 
factor for cardiovascular events, patients who survive 
AKI and progress to CKD are more likely to experience 
cardio vascular events [35].
In aggregate, we propose that endpoints for clinical 
trials of AKI should be short term and medium term. The 
primary short­term endpoints should be 30­day mortality 
and AKI­free days. Medium­term endpoints should 
include 90­day to 180­day outcomes to determine 
whether permanent loss of renal function and associated 
cardiovascular events can be mitigated. The composite 
endpoint of major adverse kidney events has been 
proposed to include each of these end points.
Hypothesis: permissive hypofiltration
The approach we propose is based on four broad themes: 
(1) focus on the underlying process causing AKI, since 
there are many different mechanisms that cause AKI; 
(2) when a patient is experiencing AKI, augmenting the 
GFR and RBF may not be helpful and may in fact be 
harmful; (3) current and recommended interventions for 
AKI have the capacity to do harm; and (4) interventions 
should be focused on durable renal recovery and 
improving survival.
The first theme is obvious of course, but has important 
consequences when enacted. This theme recognizes that 
septic­associated AKI is different from nephrotoxic AKI, 
which is different from ischemic AKI caused by profound 
global hypotension (for example, cardiac arrest). The 
treatment for all AKI is therefore not necessarily about 
augmenting RBF, but rather restoring RBF when it is 
persistently inadequate.
The second theme is based on the notion that 
increasing the work of an injured organ may worsen 
outcomes. As in the example of myocardial infarction 
and ARDS, organ support during injury is a key approach 
to improving outcomes. Consistent with this concept, 
early institution of RRT has the capacity to rest the 
injured organ by limiting the solute load and mitigating 
fluid overload. As an example, much of the progress in 
abrogating the progression of CKD is focused on treating 
presumed hyperfiltration using renin–angiotensin–
aldosterone system blockade to lower the GFR and 
prevent fibrosis, thereby improving organ survival. 
Similarly, we believe that the utilization of early RRT and 
avoidance of GFR augmentation via hyperemia during 
Chawla et al. Critical Care 2012, 16:317 
http://ccforum.com/content/16/4/317
Page 3 of 5
AKI may have the same effect as angiotensin­converting 
enzyme inhibitors have on patients with CKD to preserve 
long­term renal function.
The third theme is based on recognizing that thermal 
control, antibiotic dosing and maintenance of electrolyte 
and volume balance must be carried out carefully during 
RRT to avoid harm. This is one of the core lessons from 
the experience of ARDS therapy; limiting the harm of the 
device–patient interaction. In order to improve out­
comes, these aspects of the care of the patient with AKI 
must be improved.
The fourth theme is based on the preclinical and 
epidemiology data that show AKI is associated with 
progression to CKD. We posit that interventions initiated 
at the time of AKI may have durable long­term effects, 
particularly on retarding the progression of incident 
CKD. The improvement long­term outcomes include, but 
are not limited to, improvement in survival, a decreased 
incidence of CKD and fewer cardiovascular events.
testing the hypothesis: trial design
We suggest a conceptual trial design to test our 
hypothesis. The study population would consist of 
patients with RIFLE/Acute Kidney Injury Network 
stage  2 or greater AKI who also have evidence of an 
elevated AKI biomarker that predicts a high likelihood of 
persistence or progression of AKI. Patients would then be 
randomized to one of three arms: standard care, 
protocolized AKI management, and protocolized AKI 
management plus experimental agent.
The standard care arm would involve conservative 
management and monitoring for a need to begin RRT. If 
required (as assessed by routine clinical judgment), 
CRRT should be delivered at a dose of 20 to 25 cm3/kg/
hour for patients on vasopressors. Patients not requiring 
vasopressors should receive thrice­weekly hemodialysis 
with weekly Kt/V ≥3.6. Additional management should 
be as per clinical judgment.
The AKI protocolized management arm would consist 
of early initiation of RRT based on the criteria presented 
in Table  1, and then protocolized CRRT management 
would be as follows: CRRT delivered at a dose of 20 to 
25  cm3/kg/hour for patients on vasopressors, or thrice­
weekly hemodialysis with weekly delivered Kt/V ≥3.6 for 
patients not requiring vasopressors; maintenance of 
normothermia unless otherwise indicated; avoidance of 
hypophos pha temia; antibiotic dosing based on delivered 
RRT dose; and maintenance of volume and electrolyte 
balance.
Multiple candidate agents could be tested in the 
protocolized AKI management plus therapeutic agent 
arm of the study. The goal of the therapeutic agent would 
be to decrease mortality, enhance renal recovery and 
decrease the incidence of long­term loss of renal 
function. As an example, preclinical models show that 
angiotensin­converting enzyme inhibition given at the 
time of AKI decreases the incidence of renal fibrosis 
during recovery [36]. Other agents that may prove 
successful include those that modulate the cell cycle or 
agents that block transforming growth factor beta or that 
target a variety of inflammatory pathways. Pilot and 
feasibility studies could start with variations of the 
approaches proposed.
Conclusion
AKI is a syndrome with a multitude of causes and is 
associated with a high risk for mortality or permanent 
loss of renal function. Our current understanding of the 
most common causes of AKI is limited. A change in the 
approach to AKI that shifts away from short­term 
endpoints such as death or dialysis and instead focuses 
on improving longer­term survival and mitigating 
permanent renal damage is likely to be more fruitful. In 
addition, we suggest that augmenting renal function via 
increasing the RBF or GFR during AKI may actually 
worsen outcomes. Resting the kidney and providing early 
RRT analogous to the approach in the treatment of ARDS 
may prove to be a more effective strategy to improve 
survival and decrease permanent loss of kidney function 
for patients with AKI.
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